Literature DB >> 26256263

The Chronic Obstructive Sialadenitis Symptoms Questionnaire to assess sialendoscopy-assisted surgery.

Annick Aubin-Pouliot1, Elise A Delagnes2, David W Eisele3, Jolie L Chang4, William R Ryan5.   

Abstract

OBJECTIVES/HYPOTHESIS: Introduce the Chronic Obstructive Sialadenitis Symptoms (COSS) questionnaire to quantify chronic sialadenitis symptoms and assess the impact of sialendoscopic-assisted salivary duct surgery (SASDS). STUDY
DESIGN: Retrospective outcome symptoms questionnaire study.
METHODS: The COSS questionnaire assesses the severity of sialadenitis symptoms from 0 to 100. Patients who underwent SASDS from April 2006 to December 2013 completed the COSS questionnaire and the ShortForm8 Health Survey (SF-8) based on current symptoms, and reported whether they had complete, partial, or no symptomatic response to SASDS.
RESULTS: Sixty-six of the 156 (43%) contacted patients completed the questionnaires who had had symptoms in 26 submandibular ducts and 53 parotid ducts. The mean COSS score was higher for parotid ducts (12.0; interquartile range [IQR] 1.0-20.0) than for submandibular ducts (7.6; IQR 0.5-15.0) but not significantly so (P = 0.20). Thirty-eight (60%) patients reported complete resolution of symptoms, with a mean COSS score of 4.5 (IQR 0-7). Twenty-one (33%) patients reported partial resolution, with a mean COSS score of 18.5 (IQR 11.3-22.8). Five (8%) patients reported no improvement, with a mean COSS score of 25.1 (IQR 15.2-35). Thirty-six (46%) ducts with sialoliths had a significantly lower mean COSS score (5.8; IQR 0-9.5) compared to those without sialoliths (14.2; IQR 4.5-21.5, P = 0.0004). There was no significant difference in SF-8 survey scores between these groups.
CONCLUSION: The COSS questionnaire is a novel survey instrument to measure obstructive sialadenitis symptom severity that could be helpful in defining outcomes of SASDS. COSS scores under 10 correlate with complete resolution of symptoms, whereas scores between 10 and 25 correlate with partial resolution.
© 2015 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Sialendoscopy; chronic obstructive sialadenitis; chronic obstructive sialadenitis symptoms; outcomes; parotid; questionnaire; salivary duct surgery; sialolith; submandibular; symptoms

Mesh:

Year:  2015        PMID: 26256263     DOI: 10.1002/lary.25521

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  Botulinum toxin for chronic parotid sialadenitis: A case series and systematic review.

Authors:  Madeleine P Strohl; Chia-Fan Chang; William R Ryan; Jolie L Chang
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-05-02

2.  Quality of life after sialendoscopy: prospective non-randomized study.

Authors:  Giulianno Molina Melo; Murilo Catafesta Neves; Marcello Rosano; Christiana Maria Ribeiro Salles Vanni; Marcio Abrahao; Onivaldo Cervantes
Journal:  BMC Surg       Date:  2022-01-08       Impact factor: 2.102

3.  A pretest-posttest pilot study for the development and preliminary validation of a tool for the clinical assessment of radioiodine induced sialadenitis.

Authors:  Andri Christou; Evridiki Papastavrou; Anastasios Merkouris; Andreas Charalambous
Journal:  SAGE Open Med       Date:  2021-09-01

4.  Novel Multidisciplinary Salivary Gland Society (MSGS) Questionnaire: An International Consensus.

Authors:  Samanta Buchholzer; Frédéric Faure; Livia Tcheremissinoff; François R Herrmann; Tommaso Lombardi; Siu-Kwan Ng; Jean-Michel Lopez; Urs Borner; Robert L Witt; Robert Irvine; Olivier Abboud; Claudio R Cernea; Shirish Ghan; Takeshi Matsunobu; Zahoor Ahmad; Randall Morton; Aleksandar Anicin; Emad A Magdy; Rashid Al Abri; Iordanis Konstantinidis; Pasquale Capaccio; Hila Klein; Vincent Vander Poorten; Davide Lombardi; Bernard Lyons; Hussain Al Rand; George Liao; Jeong K Kim; Sethu Subha; Richard Y-X Su; Chin-Hui Su; Franciscus Boselie; Raphaël Andre; Jörg D Seebach; Francis Marchal
Journal:  Laryngoscope       Date:  2021-07-08       Impact factor: 2.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.